Vaccinex (VCNX) announced that on December 16, 2024, the Company received written notice from the Office of General Counsel of The Nasdaq Stock Market indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice indicated that trading in the Company’s shares of common stock on Nasdaq will be suspended effective at the open of trading on Wednesday, December 18, 2024. Upon suspension of the trading of its Common Stock on Nasdaq, the Company expects that its Common Stock will be quoted under its existing symbol “VCNX” on the OTC Markets Group.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VCNX:
- Vaccinex reports Q3 EPS ($2.83) vs. ($15.25) last year
- Vaccinex provides update on ActivMAb platform
- Vaccinex to preset new biomarker data on HNSCC
- Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab
- Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
